---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-009362"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:50:01.696957+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Roivant and Immunovant announce positive Phase 3 batoclimab MG results and initial Phase 2b CIDP results

## Summary
- Phase 3 MG study met primary endpoint with 5.6-point MG-ADL improvement at 12 weeks in high-dose batoclimab arm.
- Initial CIDP Phase 2b Period 1 data showed 1.8-point aINCAT improvement and 84% responder rate in patients with ≥70% IgG reduction.
- Immunovant plans to initiate registrational studies for IMVT-1402 in MG and CIDP.
- Deeper IgG reductions correlated with better clinical outcomes across both studies.
- Conference call held on March 19, 2025 at 8:00 a.m. ET to discuss results.

## SEC filing metadata
- accession: 0001140361-25-009362
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125009362/0001140361-25-009362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125009362/ef20045740_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-009362
- JSON: https://secwatch.observer/filing/0001140361-25-009362.json
- Plain text: https://secwatch.observer/filing/0001140361-25-009362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.